A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects with Severe Alcohol-Associated Hepatitis

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512913-42-00

Acronym

787-201

Enrollment

Registered

2024-05-22

Start date

2023-08-21

Completion date

Unknown

Last updated

2025-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe Alcohol-Associated Hepatitis

Brief summary

Marker of Efficacy - Lille score (response) at Day 7

Interventions

DRUGPlacebo

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Marker of Efficacy - Lille score (response) at Day 7	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026